October 27, 2009

Brachytherapy May Reduce Burden of Treatment and Further Improve Visual Acuity

Posted in: Research and Developments, Therapies, Treatments, and Procedures

San Francisco, CA (PRWEB) October 27, 2009 — NeoVista, Inc. made public at the American Academy of Ophthalmology meeting the company’s interim study results from the preliminary study MERITAGE-I. The study was designed to examine the company’s novel epimacular brachytherapy procedure when used in patients that require chronic anti-VEGF treatment for wet AMD. Brachytherapy involves radiation treatment delivered by a small plaque sewn to the sclera (the white covering of the eyeball).

The study enrolled patients that had as many as 23 injections of anti-VEGF therapy before receiving epimacular brachytherapy. All patients that entered the study were required to have received a minimum of 8 injections in the past 12 months or 6 injections in the past 6 months preceding enrollment.

Preliminary study results (n=16) suggest that a single procedure of epimacular brachytherapy can further improve visual acuity in a majority of this patient population while decreasing the number of injections required based on Optical Coherence Tomography imaging after the brachytherapy procedure. Most importantly, 63% of patients enrolled in the study experienced improvement in their visual acuity while 50% of patients gained 5 or more letters of visual acuity at 6 months.

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann